文献速递神经肿瘤

遗传决定的端粒长度与胶质瘤风险的关系

Relationship between genetically determined telomere length and glioma risk.
PubMed 文献 · Neuro Oncol · 2022-01-01

研究利用全基因组关联数据(LTL 78 592人,胶质瘤12 488例/18 169对照),通过孟德尔随机化分析发现遗传性增加的LTL显著增加胶质瘤风险(OR 4.79, 95%CI 2.11-10.85)。SMR确认了3q26.2、5p15.33、10q24.33和20q13.3等位点,并提示1q42.12、6p21.3等新风险位点。

要点

  • 遗传性端粒长度增加与胶质瘤风险升高相关。
  • 多个端粒相关基因位点(如TERC、TERT)与胶质瘤风险关联。
  • 研究提示PARP1、PRRC2A等基因可能参与胶质瘤病因。

核心结论

  • 遗传决定的端粒长度增加与胶质瘤风险升高显著相关,扩展了端粒相关基因在胶质瘤发生中的作用。

研究设计与样本

  • 基于全基因组关联研究数据的经典与摘要孟德尔随机化分析,辅以异质性依赖工具检验,样本包括LTL 78 592人和胶质瘤12 488例/18 169对照。

主要发现

  • 遗传性增加的LTL与胶质瘤风险相关,随机效应逆方差加权OR每1个标准差增加为4.79(95%CI 2.11-10.85; P=1.76×10-4)。
  • SMR确认了3q26.2(TERC; PSMR=1.33×10-5)、5p15.33(TERT; PSMR=9.80×10-27)、10q24.33(STN1; PSMR=4.31×10-5)和20q13.3(STMN3/RTEL1; PSMR=2.47×10-4)位点。
  • 分析提示1q42.12(PSMR=1.55×10-2)、6p21.3(PSMR=9.76×10-3)、6p22.2(PSMR=5.45×10-3)、7q31.33(PSMR=6.52×10-3)和11q22.3(PSMR=8.89×10-4)为胶质瘤风险位点。
  • 涉及PARP1、PRRC2A、CARMIL1、POT1和ATM-NPAT1的遗传变异被提示与胶质瘤病因相关。

局限性

  • 结果受连锁不平衡模式影响,部分基因关联的解读复杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Telomere maintenance is increasingly recognized as being fundamental to glioma oncogenesis with longer leukocyte telomere length (LTL) reported to increase risk of glioma. To gain further insight into the relationship between telomere genetics and risk of glioma, we conducted several complementary analyses, using genome-wide association studies data on LTL (78 592 individuals) and glioma (12 488 cases and 18 169 controls). METHODS: We performed both classical and summary Mendelian randomization (SMR), coupled with heterogeneity in dependent instruments tests, at genome-wide significant LTL loci to examine if an association was mediated by the same causal variant in glioma. To prioritize genes underscoring glioma-LTL associations, we analyzed gene expression and DNA methylation data. RESULTS: Genetically increased LTL was significantly associated with increased glioma risk, random-effects inverse variance weighted ORs per 1 SD unit increase in the putative risk factor (odds ratio [OR]SD) 4.79 (95% confidence interval: 2.11-10.85; P = 1.76 × 10-4). SMR confirmed the previously reported LTL associations at 3q26.2 (TERC; PSMR = 1.33 × 10-5), 5p15.33 (TERT; PSMR = 9.80 × 10-27), 10q24.33 (STN1 alias OBFC1; PSMR = 4.31 × 10-5), and 20q13.3 (STMN3/RTEL1; PSMR = 2.47 × 10-4) glioma risk loci. Our analysis implicates variation at 1q42.12 (PSMR = 1.55 × 10-2), 6p21.3 (PSMR = 9.76 × 10-3), 6p22.2 (PSMR = 5.45 × 10-3), 7q31.33 (PSMR = 6.52 × 10-3), and 11q22.3 (PSMR = 8.89 × 10-4) as risk factors for glioma risk. While complicated by patterns of linkage disequilibrium, genetic variation involving PARP1, PRRC2A, CARMIL1, POT1, and ATM-NPAT1 was implicated in the etiology of glioma. CONCLUSIONS: These observations extend the role of telomere-related genes in the development of glioma.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Saunders CN, Kinnersley B, Culliford R, et al. Relationship between genetically determined telomere length and glioma risk. Neuro Oncol. 2022. PMID: 34477880. doi:10.1093/neuonc/noab208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。